As of Friday close, Ginkgo Bioworks Holdings Inc.’s (NYSE:DNA) stock traded at $2.04. The average number of shares traded per day over the past five days has been 21,197,020 shares. 1 time new highs have been achieved over the past 5 days, with a -$0.40 fall in that time frame. In the last twenty days, the average volume was 24,562,459, while in the previous 50 days, it was 23,945,119.
Since last month, DNA stock rose 18.60%. Shares of the company fell to $1.67 on 07/06/23, the lowest level in the past month. A 52-week high of $4.91 was reached on 07/19/23 after having rallying from a 52-week low of $1.12. Since the beginning of this year, DNA’s stock price has risen by 20.71% or $0.35, and marked a new high 9 times. However, the stock has declined by -58.45% since its 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
DNA stock investors should be aware that Ginkgo Bioworks Holdings Inc. (DNA) stock had its last reported insider trading activity 2 days ago on Aug 03. Kelly Jason R disposed of 100,000 shares for $2.04 on Aug 03. It resulted in a $204,300 divestment by the insider. Canton Barry sold 37,650 shares at an average price of $2.04 on Aug 03. The insider now owns 13,127,544 shares following the transaction. On Aug 03, Shetty Reshma P. sold 37,650 shares at $2.04 apiece. The transaction was valued at $76,919.
Valuation Metrics
The stock’s beta is 1.21. Besides these, the trailing price-to-sales (P/S) ratio of 9.44, the price-to-book (PB) ratio of 2.43.
Financial Health
In the three months ended March 30, Ginkgo Bioworks Holdings Inc.’s quick ratio stood at 6.90, while its current ratio was 6.90, showing that the company is able to pay off its debt. On the profitability front, the trailing twelve-month gross margin is 63.80% percent. Based on annual data, DNA earned $273.49 million in gross profit and brought in $477.71 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -124.50%. Return on equity (ROE) for the past 12 months was -108.90%.
According to the earnings report, the company had a lower net income in the recent quarter than it did in the previous quarter. While analysts expected Ginkgo Bioworks Holdings Inc. to report -$0.09 quarterly earnings, the actual figure was -$0.11 per share, beating the consensus estimate by -22.20%. During the quarter, the company generated -$196.79 million in EBITDA. The liabilities of Ginkgo Bioworks Holdings Inc. were 809.62 million at the end of its most recent quarter ended March 30, and its total debt was $404.1 million. The value of shareholders’ equity is $1.97 billion.
Technical Picture
This quick technical analysis looks at Ginkgo Bioworks Holdings Inc.’s (DNA) price momentum. With a historical volatility rate of 107.33%, the RSI 9-day stood at 41.94% on 04 August.
With respect to its five-day moving average, the current Ginkgo Bioworks Holdings Inc. price is down by -16.39% percent or -$0.40. At present, DNA shares trade +15.25% above its 20-day simple moving average and +51.11% percent above its 100-day simple moving average. However, the stock is currently trading approximately +34.21% above its SMA50 and -22.43% below its SMA200.
Stochastic coefficient K was 10.40% and Stochastic coefficient D was 29.86%, while ATR was 0.19. Given the Stochastic reading of 16.53% for the 14-day period, the RSI (14) reading has been calculated as 47.11%. As of today, the MACD Oscillator reading stands at -0.23, while the 14-day reading stands at -0.26.
Analyst Ratings
Ginkgo Bioworks Holdings Inc. downgraded its rating on Ginkgo Bioworks Holdings Inc. (NYSE: DNA) to a Sell in a note to investors on June 02, 2023. The analysts firm previously had a Neutral rating on the stock.Ginkgo Bioworks Holdings Inc. (DNA) has been rated Overweight by analysts. According to 1 brokerage firm, DNA is a sell, and 2 firms recommend it is a Hold. There are 1 analyst who say the stock is underweight. A total of 1 analyst rate Ginkgo Bioworks Holdings Inc. stock as buy, with 4 recommending it as overweight.
With a median target price of $3.20, the current consensus forecast for the stock is $1.25 – $12.00. Based on these forecasts, analysts predict Ginkgo Bioworks Holdings Inc. (DNA) will achieve an average price target of $4.24.
